BMS-986340 + docetaxel

BMS-986340 + docetaxel is an investigational combination therapy for advanced solid tumors, being evaluated in a first-in-human, phase 1/2 clinical trial. BMS-986340 is a monoclonal antibody immunotherapy developed by Bristol Myers Squibb, designed to modulate the immune system to target and destroy cancer cells. Docetaxel is a well-established cytotoxic chemotherapy agent that stabilizes microtubules, inhibiting cell division and inducing apoptosis in cancer cells. The study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of this combination in patients with advanced or metastatic cancers, including non-small cell lung cancer, colorectal cancer, gastric/gastroesophageal junction adenocarcinoma, cervical cancer, and other selected tumors[1][2][3][4][5].